I have come to learn (the hard way) that Mike is the exception to EVERY rule. While the side effects were suppose to be "limited" they've hit him harder then we expected. He has been experiencing nausea, high blood pressure and weakness. We called his nurse today to see if they can start him on a nausea pill and what they suggest for the weakness. He starts a high blood pressure medicine today. He is feeling a little down but I'm determined to cheer him up!
Ta-ta for now!
Monday, May 16, 2011
Tuesday, May 10, 2011
Extra Extra Read all About it!
I won't bore you with details. If you would like to read about Mike's trial this contract was reviewed with Michael and me yesterday. It gives detail to the trial, side effects, dangers, and potential outcome. Interesting stuff...here is the link Mike's Clinical Trial .
Thursday, May 5, 2011
Michaels New Clinical Trial Starts Monday!
We received news earlier this week that the clinical trial we've been waiting for is finally open. Mike goes for and ECO and CAT Scan today (05/05/10). Monday (05/09/10) he signs for the trial and "hopefully" has success with it. Follow this link for information regarding the study: http://clinicaltrials.gov/ct2/show/NCT01330966?term=Chondrosarcoma&rank=2
This Chemo is given in pill form. Mike will take Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Courses repeat every 28 days until disease progression or unacceptable toxicity.
Here is GSK's slightly one-sided (because they're the makers) view of the drug: http://www.gsk.com/media/pressreleases/2009/2009_us_pressrelease_10039.htm
Here's hoping!
This Chemo is given in pill form. Mike will take Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Courses repeat every 28 days until disease progression or unacceptable toxicity.
Here is GSK's slightly one-sided (because they're the makers) view of the drug: http://www.gsk.com/media/pressreleases/2009/2009_us_pressrelease_10039.htm
Here's hoping!
Subscribe to:
Posts (Atom)